Error in pricing information in: Payer Coverage for Bronchial Thermoplasty: Shifting the Traditional Paradigm for Refractory Asthma Therapy

CHEST Journal ◽  
2013 ◽  
Vol 144 (5) ◽  
pp. 1743
Keyword(s):  
Asthma Therapy ◽  
Bronchial Thermoplasty ◽  
Traditional Paradigm ◽  
Refractory Asthma

Bronchial thermoplasty: A new treatment for severe refractory asthma

2011 ◽  
Vol 78 (7) ◽  
pp. 477-485 ◽  
Author(s):  
T. R. GILDEA ◽  
S. B. KHATRI ◽  
M. CASTRO
Keyword(s):  
Bronchial Thermoplasty ◽  
New Treatment ◽  
Refractory Asthma

Clinical and histopathologic predictors of therapeutic response to bronchial thermoplasty in severe refractory asthma

2021 ◽  
Author(s):  
Maha Zohra Ladjemi ◽  
Leonarda Di Candia ◽  
Nicolas Heddebaut ◽  
Camille Techoueyres ◽  
Eloise Airaud ◽  
...  
Keyword(s):  
Therapeutic Response ◽  
Bronchial Thermoplasty ◽  
Refractory Asthma

Safety of bronchial thermoplasty in patients with severe refractory asthma

2013 ◽  
Vol 111 (5) ◽  
pp. 402-407 ◽  
Author(s):  
Ian D. Pavord ◽  
Neil C. Thomson ◽  
Robert M. Niven ◽  
Paul A. Corris ◽  
Kian Fan Chung ◽  
...  
Keyword(s):  
Bronchial Thermoplasty ◽  
Refractory Asthma

Endobronchial Biopsy: A Guide for Asthma Therapy Selection in the Era of Bronchial Thermoplasty

2013 ◽  
Vol 50 (6) ◽  
pp. 634-641 ◽  
Author(s):  
Ilyssa O. Gordon ◽  
Aliya N. Husain ◽  
Jeffery Charbeneau ◽  
Jerry A. Krishnan ◽  
D. Kyle Hogarth
Keyword(s):  
Asthma Therapy ◽  
Bronchial Thermoplasty

scholarly journals Bronchial Thermoplasty in the Treatment of Severe Asthma

2020 ◽  
pp. 1-9
Author(s):  
Nightingale Syabbalo ◽  
Keyword(s):  
Severe Asthma ◽  
Inhaled Corticosteroids ◽  
Airway Disease ◽  
Airflow Limitation ◽  
Response To Treatment ◽  
High Dose ◽  
Eosinophilic Asthma ◽  
Bronchial Thermoplasty ◽  
Long Acting ◽  
Refractory Asthma

Asthma is a chronic inflammatory airway disease with several distinct phenotypes, characterized by different immunopathological pathways, clinical presentation, severity of the disease, and response to treatment. The phenotypes of asthma include eosinophilic, neutrophilic, mixed granulocytic, and paucigranulocytic asthma. Approximately 3.6-10% of patients with asthma have severe refractory disease, which is unresponsive to high dose inhaled corticosteroids (ICS), and long-acting β2-agonists (LABA). Most patients with eosinophilic asthma are responsive to corticosteroids, and interleukintargeted biologics, whereas, patients from other phenotypes, such as neutrophillic and paucigranullocytic asthma are resistant to treatment with ICS and biotherapeutics. The hallmark of severe refractory asthma is airway hyperresponsiveness, and remodeling. Histopathologically, patients with severe asthma have airway smooth muscle (ASM) hyperplasia and hypertrophy; subepithelial basement membrane thickening and fibrosis; all which contribute to fixed airflow limitation. Severe refractory asthma is very difficult to treat pharmacologically. It requires innovative therapies, such as bronchial thermoplasty which reduces the hypertrophied ASM mass and relieves the AHR, and broncoconstriction. Bronchial thermoplasty has been shown to improve asthma control, reduce severe exacerbations, hospitalizations, emergency room visits, and improve the quality of life, which persist up to 5 years following the procedure

scholarly journals A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM)

2021 ◽  
Vol Volume 14 ◽  
pp. 1019-1031
Author(s):  
Francesco Menzella ◽  
Matteo Fontana ◽  
Carla Galeone ◽  
Maria D'Amato ◽  
Giorgio Walter Canonica ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Real World ◽  
Bronchial Thermoplasty ◽  
Refractory Asthma
Sign in / Sign up

Export Citation Format

Share Document